APOB and fatty liver disease: The solution to this unresolved question is likely to be provided by two emerging initiatives: First, the completion of the ARO-ANG3 studies in patients with increased apoB containing lipoprotein levels and fatty liver disease (data presentation planned at AHA 2023).